| |
original article |
Journal |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
Drugs in Context |
2023―Jun―26 |
Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data |
Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, Helen Yearley, Wolfgang Junker, Nina Gruber, Sibyll Escher, Katrin Biereth, Sima Melnik, Julia Puschmann |
| 2 |
[GO] |
Drugs in Context |
2023―Jun―07 |
Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms |
Mikhail Kostinov, Oksana Svitich, Alexander Chuchalin, Natalya Abramova, Valery Osiptsov, Ekaterina Khromova, Dmitry Pakhomov, Vitaly Tatevosov, Anna Vlasenko, Vilia Gainitdinova, Kirill Mashilov, Nadezhda Kryukova, Irina Baranova, Anton Kostinov |
| 3 |
[GO] |
Drugs in Context |
2023―Feb―15 |
A single-centre experience rolling out an antibiotic stewardship intervention prior to and during the SARS-CoV-2 pandemic 2019-2022 |
Zahra Kassamali Escobar, Todd Bouchard, Cameron Buck, Kamaldeep Sandhu, Chloe Bryson-Cahn |
| 4 |
[GO] |
Drugs in Context |
2023―Feb―06 |
COVID-19 therapy and vaccination: a clinical narrative review |
Siddharth Chinta, Miguel Rodriguez-Guerra, Mohammed Shaban, Neelanjana Pandey, Maria Jaquez-Duran, Timothy J Vittorio |
| 5 |
[GO] |
Drugs in Context |
2022―Jun―16 |
Addressing COVID-19 vaccine hesitancy |
George Kassianos, Joan Puig-Barberà, Hannah Dinse, Martin Teufel, Özlem Türeci, Shanti Pather |
| 6 |
[GO] |
Drugs in Context |
2022―Apr―08 |
Real-world use of inhaled nitric oxide therapy in patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome |
Steven H Abman, Nicholas R Fox, M Ibrahim Malik, Sneha S Kelkar, Shelby L Corman, Sanika Rege, Jenna Bhaloo, Rachel Shah, Ren-Jay Shei, Dana Saporito, Nisreen Shamseddine, Erik DeBoer, George J Wan |
| 7 |
[GO] |
Drugs in Context |
2022―Mar―01 |
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19 |
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Luydmila Yu Akhieva, Elena V Kuntsevich, Anastasia A Troshina, Elena I Kvasova, Anton A Tikhonov, Nadezhda F Khomyakova, Francisco Harrison, Jean-François Rossi, Timothy C Hardman |
| 8 |
[GO] |
Drugs in Context |
2022―Jan―21 |
Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL* protocol |
Juan José Cerezo-Manchado, Olga Meca Birlanga, Luis García de Guadiana Romualdo, Ignacio Gil-Ortega, Antonio Martínez Francés, Teodoro Iturbe-Hernandez |
| 9 |
[GO] |
Drugs in Context |
2021―Dec―12 |
COVID-19-related adaptations to the implementation and evaluation of a clinic-based intervention designed to improve opioid safety |
Anna R Morgan, Michelle A Hendricks, Sanae El Ibrahimi, Sara E Hallvik, Brigit Hatch, Caitlin Dickinson, Dagan Wright, Michael A Fischer |
| 10 |
[GO] |
Drugs in Context |
2021―Oct―05 |
Vitamins, supplements and COVID-19: a review of currently available evidence |
Lauren Speakman, Sarah Michienzi, Melissa Badowski |
| 11 |
[GO] |
Drugs in Context |
2021―Jun―23 |
Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study |
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi |
| 12 |
[GO] |
Drugs in Context |
2021―Jun―08 |
Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic |
Tiago Torres, Marta Pereira, Maria João Paiva Lopes, Clarisse Rebelo, Pedro Andrade, Martinha Henrique, Hugo Oliveira, Paulo Ferreira, Gabriela Marques Pinto, Francisco Menezes Brandão, Jorge Rozeira, Paulo Filipe, Rui Tavares Bello |
| 13 |
[GO] |
Drugs in Context |
2021―May―24 |
The UK approach to COVID-19 vaccination: why was it so different? |
Peter MB English |
| 14 |
[GO] |
Drugs in Context |
2021―Mar―23 |
The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study |
Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi |
| 15 |
[GO] |
Drugs in Context |
2021―Feb―15 |
The race to a COVID-19 vaccine: opportunities and challenges in development and distribution |
Rodrigo M Burgos, Melissa E Badowski, Emily Drwiega, Samaneh Ghassemi, Nikki Griffith, Fischer Herald, Mikayla Johnson, Renata O Smith, Sarah M Michienzi |
| 16 |
[GO] |
Drugs in Context |
2021―Jan―29 |
Current treatment in COVID-19 disease: a rapid review |
Miguel Rodriguez-Guerra, Preeti Jadhav, Timothy J Vittorio |
| 17 |
[GO] |
Drugs in Context |
2020―Sep―16 |
Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol |
Teodoro Iturbe-Hernandez, Luis García de Guadiana Romualdo, Ignacio Gil Ortega, Antonio Martínez Francés, Olga Meca Birlanga, Juan José Cerezo-Manchado |
| 18 |
[GO] |
Drugs in Context |
2020―Jun―29 |
Coronavirus disease 2019 (COVID-19): latest developments in potential treatments |
Kam Lun Hon, Karen Ka Yan Leung, Alexander KC Leung, Su Yun Qian, Vivian PY Chan, Patrick Ip, Ian CK Wong |
| 19 |
[GO] |
Drugs in Context |
2020―Jun―20 |
Can vitamins and/or supplements provide hope against coronavirus? |
Sarah M Michienzi, Melissa E Badowski |
| 20 |
[GO] |
Drugs in Context |
2020―Jun―10 |
Neurological features of COVID-19 and their treatment: a review |
Daniele Orsucci, Elena Caldarazzo Ienco, Gianpaolo Nocita, Alessandro Napolitano, Marco Vista |
| 21 |
[GO] |
Drugs in Context |
2020―May―23 |
A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic |
Matteo Bassetti, Paolo Pelosi, Chiara Robba, Antonio Vena, Daniele Roberto Giacobbe |
| 22 |
[GO] |
Drugs in Context |
2020―May―20 |
The journey of remdesivir: from Ebola to COVID-19 |
Joe Pardo, Ashutosh M Shukla, Gajapathiraju Chamarthi, Asmita Gupte |
| 23 |
[GO] |
Drugs in Context |
2020―May―17 |
Pharmacological treatment of COVID-19: lights and shadows |
Francesco Menzella, Mirella Biava, Chiara Barbieri, Francesco Livrieri, Nicola Facciolongo |
| 24 |
[GO] |
Drugs in Context |
2020―May―13 |
Psoriasis, biologic therapy, and the pandemic of the 21st century |
Miguel Nogueira, Ron Vender, Tiago Torres |
| 25 |
[GO] |
Drugs in Context |
2020―May―10 |
Facing the COVID-19 outbreak in children with cancer |
Antonio Ruggiero, Alberto Romano, Giorgio Attinà |
| 26 |
[GO] |
Drugs in Context |
2020―Apr―27 |
Chloroquine and hydroxychloroquine in the context of COVID-19 |
Ashutosh M Shukla, Lennox K Archibald, Aparna Wagle Shukla, Hiren J Mehta, Kartikeya Cherabuddi |
|
